Literature DB >> 11228176

Expression of chemokines and chemokine receptors during human renal transplant rejection.

S Segerer1, Y Cui, F Eitner, T Goodpaster, K L Hudkins, M Mack, J P Cartron, Y Colin, D Schlondorff, C E Alpers.   

Abstract

Infiltration of renal allografts by leukocytes is a hallmark of acute transplant rejection. Chemokines attract leukocytes bearing specific chemokine receptors, and the specific leukocyte chemokine receptor phenotype is associated with types of immune responses, ie, T helper subtype 1 (Th1; CXC chemokine receptor 3 [CXCR3], CC chemokine receptor 5 [CCR5]) versus Th2 (CCR3, CCR4, CCR8). We studied the expression of the chemokine monocyte chemoattractant protein-1 and the chemokine receptors CCR2B and CXCR4 messenger RNA (mRNA) by in situ hybridization, as well as the chemokine receptors Duffy antigen receptor for chemokines (DARC) and CCR5 protein by immunohistochemistry in renal biopsy specimens with acute cellular rejection (n = 12) and acute vascular rejection (n = 8), transplant nephrectomy specimens (n = 6), and normal areas of tumor nephrectomy specimens (n = 5). CC chemokines and CC chemokine receptor mRNA expression were evaluated by ribonuclease protection assay in specimens from four transplant nephrectomies and one tumor nephrectomy. Upregulation of mRNAs for the chemokines, interferon-inducible protein-10 (IP-10); regulated on activation normal T-cell expressed and secreted; macrophage inflammatory protein-1alpha (MIP-1alpha); MIP-1beta; and lymphotactin, as well as the chemokine receptors, CCR2 and CCR5, were documented during allograft rejection. CCR1 mRNA was detectable in both allografts and controls, but CCR3 and CCR8 were absent. The number of CXCR4, CCR5, and CCR2B mRNAs expressing leukocytes and DARC-positive vessels increased during rejection episodes. CXCR4 mRNA was the most widely expressed. Leukocytes in diffuse interstitial infiltrates were mainly CCR5 positive, but in areas in which leukocytes formed nodular aggregates of infiltrating cells, the number of CCR5-positive cells was low. Instead, leukocytes in these nodular aggregates mainly expressed CXCR4. DARC was expressed on peritubular capillaries, where it was upregulated in areas of interstitial infiltration. Induction of chemokines during renal allograft rejection is accompanied by infiltration of leukocytes bearing the respective chemokine receptors. The upregulation of the CXCR3 ligand IP-10, as well as CCR5 and its ligands, in the absence of CCR3 and CCR8 is indicative that renal allograft rejection is primarily the result of a Th1-type immune response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228176

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  48 in total

Review 1.  Chemokine expression and function at the human maternal-fetal interface.

Authors:  Penelope M Drake; Kristy Red-Horse; Susan J Fisher
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

2.  Analysis of gene polymorphisms in the regulatory region of MCP-1, RANTES, and CCR5 in liver transplant recipients.

Authors:  Bernd Schröppel; Michael Fischereder; Marvin Lin; Brad Marder; Tom Schiano; Bernhard K Krämer; Barbara Murphy
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

3.  A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation.

Authors:  Hans-Joachim Anders; Volker Vielhauer; Michael Frink; Yvonne Linde; Clemens D Cohen; Simone M Blattner; Matthias Kretzler; Frank Strutz; Matthias Mack; Hermann-Josef Gröne; James Onuffer; Richard Horuk; Peter J Nelson; Detlef Schlöndorff
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

4.  Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection.

Authors:  J A Jackson; E J Kim; B Begley; J Cheeseman; T Harden; S D Perez; S Thomas; B Warshaw; A D Kirk
Journal:  Am J Transplant       Date:  2011-08-03       Impact factor: 8.086

5.  Lymphatic precollectors contain a novel, specialized subpopulation of podoplanin low, CCL27-expressing lymphatic endothelial cells.

Authors:  Nikolaus Wick; Daniela Haluza; Elisabeth Gurnhofer; Ingrid Raab; Marie-Theres Kasimir; Michael Prinz; Carl-Walter Steiner; Christina Reinisch; Anny Howorka; Pietro Giovanoli; Sabine Buchsbaum; Sigurd Krieger; Erwin Tschachler; Peter Petzelbauer; Dontscho Kerjaschki
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

6.  Chemokines and their receptors in human renal allotransplantation.

Authors:  Denise J Lo; Tim A Weaver; David E Kleiner; Roslyn B Mannon; Lynn M Jacobson; Bryan N Becker; S John Swanson; Douglas A Hale; Allan D Kirk
Journal:  Transplantation       Date:  2011-01-15       Impact factor: 4.939

7.  Allo-specific immune response profiles indicative of acute rejection in kidney allografts using an in vitro lymphocyte culture-based model.

Authors:  Sobhana Mahakur; Biman Saikia; Mukut Minz; Ranjana W Minz; Ritambhra Nada; Shashi Anand; Ashish Sharma; Vivekanand Jha; Neha Joshi; Lekha Goel; Amit Arora; Kusum Joshi
Journal:  Clin Exp Nephrol       Date:  2017-08-28       Impact factor: 2.801

Review 8.  Biomarkers in Solid Organ Transplantation.

Authors:  John Choi; Albana Bano; Jamil Azzi
Journal:  Clin Lab Med       Date:  2018-12-17       Impact factor: 1.935

9.  Viral macrophage inflammatory protein-II improves acute rejection in allogeneic rat kidney transplants.

Authors:  Jens Bedke; Tomislav Stojanovic; Eva Kiss; Carl-Ludwig Behnes; Amanda E Proudfoot; Hermann-Josef Gröne
Journal:  World J Urol       Date:  2010-04-18       Impact factor: 4.226

10.  Efficient renal recruitment of macrophages and T cells in mice lacking the duffy antigen/receptor for chemokines.

Authors:  Volker Vielhauer; Ramanjaneyulu Allam; Maja T Lindenmeyer; Clemens D Cohen; Dan Draganovici; Jana Mandelbaum; Nuru Eltrich; Peter J Nelson; Hans-Joachim Anders; Monika Pruenster; Antal Rot; Detlef Schlöndorff; Stephan Segerer
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.